Background: In patients with diabetes mellitus, hyperfiltration precedes the development of
| INTRODUCTION
In Brenner's hyperfiltration theory, elevations in single nephron glomerular filtration rate (GFR) first lead to intraglomerular hypertension and pressure-related injury. [1] [2] [3] After this initial hyperfiltration phase, pathologic glomerulosclerosis ensues and whole kidney GFR begins to decline in parallel with the initial rise in albuminuria. In non-sickle cell anemia (SCA) pediatric and adult SCA populations, hyperfiltration is defined as an estimated GFR (eGFR) > 140 mL/min/1.73 m 2 . [4] [5] [6] Using this definition, most pediatric SCA patients have hyperfiltration beginning early in childhood. For example, in the Baby HUG study, the mean eGFR at 4 years of age was 146 mL/min/1.73 m 2 and the 75th percentile eGFR was around 180 mL/min/1.73 m 2 . 7, 8 Previous studies in SCD show that eGFR increases during early childhood, plateaus during adolescence, and then begins to drop as progressive CKD continues. 9, 10 Approximately 90% of SCA patients aged 20-year old have an eGFR >140 mL/min/1.73 m 2 .
5,9-12
About 10%-30% of pediatric patients with sickle cell anemia (SCA) develop albuminuria during childhood. 9, 10, 13, 14 Risk factors for the development of albuminuria in pediatric sickle cell disease include increasing age, elevated blood pressure, leukocytosis, anemia, and increased hemolytic markers. 9, 10, 13, [15] [16] [17] However, these prior studies are often cross-sectional, use only a single urine albumin to creatinine ratio to define albuminuria, and may not account for the age at which albuminuria is detected.
Some cross-sectional pediatric sickle cell studies suggest an association between elevated estimated glomerular filtration rate (eGFR) and albuminuria while other pediatric studies do not. The timing of GFR measurements could explain the conflicting results as GFR changes over time from normal, to hyperfiltration, to progression of kidney damage with resultant GFR decline. In our prior study of 152 children with SCA, the eGFR in patients with new onset albuminuria was not statistically different compared to those without albuminuria but 1/3 of those patients did not have eGFR measured early in life. 17 Thus, studies designed to evaluate the association and timing of hyperfiltration with albuminuria in SCA patients are greatly needed to determine if the Brenner Hypothesis is applicable to the SCA population.
Because progression to proteinuria, chronic kidney disease, and end-stage renal disease are well-established risk factor for early mortality, identifying SCA patients with persistent albuminuria early in life or before glomerulosclerosis and albuminuria occurs is important as it would allow institution of potentially reno-protective therapy. [20] [21] [22] As with most complications of sickle cell disease, organ injury begins in the pediatric age group. The majority of SCA patients experience an elevation of GFR during early childhood and almost 30% of adolescents develop albuminuria. Therefore, we sought to determine the temporal relationship between early hyperfiltration and the age at which persistent albuminuria first occurs. We tested the hypothesis that pediatric patients with hyperfiltration during early childhood develop albuminuria earlier in life than similar patients without early hyperfiltration.
| METHODS

| Study population
We have enrolled 185 participants with HbSS or SB0 thalassemia 5-21 years of age in a UAB IRB approved prospective cohort study to understand progression to SCA nephropathy. During the prospective study, participants complete annual estimations of GFR by cystatin C and untimed urine measurements for albumin to creatinine ratios.
In addition, we abstracted from the electronic medical records retrospective data on eGFR measurements and urine albumin to creatinine ratios obtained as standard of care prior to enrollment in the cohort study. We removed one patient with chronic kidney disease who developed biopsy-proven granulomatous kidney disease not associated with sickle cell anemia.
| Definition of early hyperfiltration
For this study, we defined early hyperfiltration according to eGFR measurements obtained from 4 to 10 years of age during outpatient well- 
| Additional risk variables
We abstracted the hemoglobin [Hb] , and the type of SCA therapy (chronic transfusion, hydroxyurea, and no SCA modifying therapy)
from the outpatient well-child sickle cell clinic visit in which the eGFR was measured. We categorized patients with severe anemia if their mean hemoglobin was ≤8.0 g/dL from 4 to 10 years of age. 17 We categorized therapy as the most common therapy prescribed from 4 to 10 years of age.
| Primary outcome-persistent albuminuria
As standard of care, we prospectively collect urine albumin creatinine ratios annually during outpatient well-child clinic visits but acknowledge issues with adherence to annual clinic visits. Among the 91 participants, we abstracted 415 untimed urine albumin to creatinine ratios and defined albuminuria as an albumin to creatinine ratio > 30 mg/g as measured by a Siemens DCA Vantage Analyzer. To confirm albuminuria in the absence of a first morning void on all participants, we defined persistent albuminuria as two abnormal urine microalbumin to creatinine ratios over three consecutive measurements. For time to event analysis, we identified the age at which the first episode of persistent albuminuria occurred.
| Statistical analysis
We summarized the basic demographic and clinical information of the cohort by presenting counts with percentages for categorical variables and mean and standard deviations for continuous variables. We used chi square test to compare proportions and t-test to compare means between participants with and without hyperfiltration. We performed descriptive and univariate statistics to characterize the natural history of the development of albuminuria.
We fitted regression models to model the relationship between GFR and age stratified by persistent albuminuria using linear, quadratic, and cubic polynomials. We found that the best fit is a quadratic function. We also obtained the 95% confidence intervals and used these to form a band around the fitted lines. As the development of albuminuria is age dependent, we performed time to event analysis to determine differences between groups and timing of the development of the first episode of persistent albuminuria. We evaluated groups 
| RESULTS
The characteristics of the entire cohort, as well as stratified by with or without hyperfiltration during early childhood, are presented in Table 1 .
No significant differences were identified in the characteristics of patients with and without hyperfiltration. Over 70% of participants were prescribed a SCA modifying therapy during early childhood and 1/3 had a mean hemoglobin level ≤ 8 g/dL. We identified 12 (13%) participants with persistent albuminuria. The median current age of participants identified with persistent albuminuria was 11 years (range 6-13 years) and the median age of participants that have not developed As the age of the participants impacts the development of persistent albuminuria, we performed a time to event analysis which shows that participants categorized with hyperfiltration during early childhood develop persistent albuminuria at an earlier age than participants without hyperfiltration (log-rank, P = 0.004, Figure 2A ). Using the mean eGFR during early childhood as a continuous variable in a proportional hazard analysis, we also demonstrated that eGFR was associated with the development of persistent of albuminuria at an earlier age (P = 0.004). To determine if severe anemia, and type of SCA therapy were possible confounders, we first explored their individual association with albuminuria. Participants with severe anemia nonsignificantly developed persistent albuminuria at an earlier age than participants with normal to higher mean hemoglobin (log-rank P = 0.07, Figure 2B ). Using a continuous variable of mean hemoglobin level during early childhood in a proportional hazard model, lower hemoglobin also did not reach statistical significance. For every 1 g/dL increase in hemoglobin, the risk ratio for developing persistent proteinuria decreased by 0.55 (P = 0.06). The therapy most frequently prescribed (hydroxyurea, transfusion, or no sickle cell disease modifying therapy) Patients with hyperfiltration defined as mean eGFR ≥180 mL/min/1.73 m 2 during early childhood (from 4 to 10 years). Patients without hyperfiltration defined as mean eGFR <180 mL/min/1.73 m 2 during early childhood (from 4 to 10 years).
during early childhood did not significantly impact time to develop persistent albuminuria (log-rank P = 0.39, Figure 2C ) nor did any sickle cell therapy versus no therapy (log-rank, P = 0.21, Figure 2D ). As hemoglobin level and therapy may impact hyperfiltration, we fitted Cox model with hyperfiltration adjusted for hemoglobin category and therapy on the development of persistent albuminuria at an earlier age. Using categorical variables of hyperfiltration and severe anemia, hyperfiltration was significantly (P = 0.008) associated with earlier development of albuminuria but severe anemia was not statistically significant (P = 0.12). For hyperfiltration and any sickle cell therapy versus no sickle cell therapy, hyperfiltration was again significant (P = 0.02) but therapy was not significant (P = 0.55). In addition, we examined therapy and severe anemia without hyperfiltration and identified no significant association between sickle cell therapy (0.46) and severe anemia (P = 0.13) on the earlier development of albuminuria.
While we a priori select a definition for hyperfiltration as a mean eGFR ≥180 mL/min/1.73m 2 , we also performed a sensitivity analysis for different mean eGFR measurements. The best cut-off for mean eGFR for persistent albuminuria was an eGFR 185 mL/min/1.73m 2 which demonstrated a sensitivity of 75% and specificity of 69%. An 
| DISCUSSION
This study provides several novel findings important to clinical care and future research in SCA nephropathy. First, we identified that patients with early hyperfiltration are more likely to progress to the earlier development of albuminuria. Therefore, clinicians should obtain eGFR during early childhood to identify patients with hyperfiltration and begin screening them for albuminuria earlier than the current NIH sickle cell guideline recommendation of 10 years of age. 23 The gold standard for measuring GFR is inulin clearance. The significant time and cost for measured studies of GFR prohibit their widespread adoption in annual standard of care screening for hyperfiltration in pediatric sickle cell disease. Serum Cystatin C and creatinine-based estimations of GFR may be more cost and time-effective for annual screening. When comparing cystatin C and creatinine equations to nuclear medicine techniques in pediatric and adult sickle cell studies, the data suggest that cystatin C estimation of GFR has a better correlation with nuclear medicine measured GFR than the current serum creatinine based equations. 9, 24, 25 Novel equations to estimate GFR using cystatin C and creatinine may be needed in pediatric sickle cell disease during hyperfiltration as the current equations for estimating GFR were developed in pediatric patients with mild to moderate CKD rather than patients with elevated GFR. 26, 27 Second, as our data show that hyperfiltration precedes albuminuria, interventional trials of therapies aimed at reducing hyperfiltration during early childhood should be prospectively evaluated. A few studies of current sickle cell modifying therapies have evaluated the impact of hydroxyurea or transfusion therapy on GFR. The prospective Baby HUG trial failed to demonstrate that hydroxyurea improves hyperfiltration during toddler ages while the smaller, nonrandomized HUSTLE study suggested that hydroxyurea may decrease GFR in an older study population. 7 One pediatric analysis compared differences in GFR between chronic transfusion, using baseline data from the TWiTCH study (mean age of participants was 10 years with 4 years of preceding transfusion), to age matched participants on hydroxyurea in the HUSTLE study. In this analysis, participants receiving chronic transfusion therapy had a significantly lower eGFR than participants on the HUSTLE study receiving hydroxyurea using 2 different creatinine-based definitions of eGFR. 40 In addition to these shorterterm randomized intervention trials to reduce hyperfiltration, longer- 28 This information is vital to determine whether sickle cell disease modifying therapies alone or the addition of renal-targeted therapies are necessary to normalize eGFR in children with sickle cell disease. One phase II young adult study evaluating 6 months of losartan therapy did not detect a change in GFR, but the majority of these participants were older with baseline albuminuria. We need longerterm studies of angiotensin inhibition in younger patients without albuminuria to evaluate this class of medication's ability to prevent or reduce hyperfiltration. Finally, the current study did not evaluate genetic variants associated with development of albuminuria including APOL1. Future research should consider screening for these genetic variants associated with albuminuria in their trial design and evaluate the impact of sickle cell modifying therapies or renoprotective agents on preventing albuminuria in children with these high-risk genetic variants. [29] [30] [31] [32] Third, this study provides important evidence of natural history changes in eGFR during childhood relevant to the current literature.
Participants with hyperfiltration and albuminuria began to have a statistical separation in eGFR around 7 years of age. The Baby HUG study did not identify a difference in GFR, as measured by DTPA, at study exit (mean age at exit: 37 months) between participants randomized to HU or placebo (146 vs 146 mL/min/1.73 m 2 , P = .84). 7 Our data suggest that an evaluation at 3-4 years of age may have been too early to identify the impact of hydroxyurea on GFR changes.
Second, our natural history data show a decline from hyperfiltration beginning around 10-13 years of age after which time we identified no difference in eGFR between those participants with and without albuminuria. This finding may explain why several cross-sectional studies, including our prior studies, evaluating eGFR at the time adolescent patients develop episodes of albuminuria have not identified an association of hyperfiltration and albuminuria. 13, 15, 19, 33, 34 Finally, additional research, potentially using biomarkers of glomerular or tubular injury are needed to better understand or predict patients at risk for progression to hyperfiltration.
This study provides the first long-term cohort to provide evidence that hyperfiltration precedes the development of albuminuria in pediatric sickle cell anemia. Despite the strengths of this data, we acknowledge the following limitations inherent to a longitudinal study involving clinical care laboratory evaluations. First, this study estimated GFR with cystatin C rather than the gold standard measurement of GFR with inulin clearance. We acknowledge that measured GFR with inulin is the gold standard, but this test is not feasible in our longitudinal study of almost 200 patients undergoing annual GFR evaluations. Cystatin C is reported as an appropriate estimation of GFR in pediatric patients with SCA, and the ease of estimating GFR with this readily available test makes our findings applicable to clinical care. 9, 24, 25 Second, the gold standard measurement for confirming albuminuria is a first morning void, but our anecdotal clinical experience is that we experience low adherence for patients completing a first morning void during an annual clinic visit. 35 Therefore, we used the definition of two of three abnormal urine measurements as suggested by KDIGO guidelines for defining albuminuria. Also, we attempted to obtain confirmatory tests at the next clinic visit (within 2 months), but the time between urine measurements was not always fixed due to nonadherence with follow-up. Third, we performed our time to event analysis in a subset of patients with eGFR obtained ear- In conclusion, we demonstrate that hyperfiltration precedes the development of albuminuria in pediatric SCA patients. Therefore, clinicians should monitor children with sickle cell anemia for hyperfiltration and screen for albuminuria earlier than 10 years of age in this higher risk population. While annual screening with cystatin C is feasible and predictive of albuminuria, we need additional research to improve methods of GFR estimation or direct measurement that are patient-friendly, cost-sensitive. As this data again demonstrate that age is an important modifier of the development of albuminuria, we recommend future cohort studies perform time to event analysis for risk factors leading to the earlier development of albuminuria. In addition, as persistent albuminuria likely represents chronic injury rather than an acute event, we suggest that future studies evaluate risk fac- 
